BOM

Photon IP is a deeptech startup located in Eindhoven, the Netherlands, focused on developing advanced technologies for photonics applications. The company specializes in application-specific semiconductors that cater to various sectors, including wearable electronics and data centers. By providing innovative solutions, Photon IP supports clients in industries such as automotive and telecommunications, aiming to enhance the functionality and efficiency of their products.

Morphotonics specializes in the development and sale of nano- and micro imprint structures, providing solutions for imprinting micro- and nanostructures on both rigid and flexible surfaces. The company employs roll-to-plate nanoimprinting technology, which allows for efficient patterning of large substrates through the sequential imprinting of small areas. In addition to these imprinting solutions, Morphotonics manufactures nanoimprint lithography machines and offers a range of associated products, including materials, stamps, and samples. Their technology enables scalable manufacturing of advanced materials and devices, catering to various industries seeking innovative micro- and nanostructured products.

SCIL Nanoimprint Solutions specializes in lithography technology designed for patterning nanostructures on large wafers. The company has developed a unique approach that merges the precision of rigid stamping with the adaptability of soft stamp techniques, effectively overcoming the limitations associated with traditional rigid lithography. This innovative technology achieves nanometer resolution, making it suitable for applications in optics and various photonic products. SCIL Nanoimprint Solutions aims to enhance customer productivity by providing optimized equipment, consumable materials, and processes that facilitate high-volume production while reducing end-product costs and improving overall functionality.

VIVOLTA specializes in the contract development and manufacturing of electrospun medical products, focusing on nanofiber-based solutions that promote the body's natural healing processes. The company has developed advanced electrospinning technologies that enable the production of medical implants, effectively replicating the human extracellular matrix in a reproducible and scalable manner. VIVOLTA's offerings include various methods such as melt electrospinning, wet electrospinning, and emulsion electrospinning, along with specialized modules and tools that enhance the efficiency of electrospinning research. Through these innovations, VIVOLTA supports medical professionals in advancing their medical concepts and improving patient outcomes.

Cristal Therapeutics BV is a clinical-stage pharmaceutical company based in Maastricht, the Netherlands, founded in 2011. The company specializes in developing nanomedicines using its proprietary CriPec platform, which transforms drugs into nanoparticles for targeted therapy. This advanced technology aims to enhance the efficacy of both new and existing drugs by improving their delivery to specific tissues and cells, thereby addressing significant medical needs, particularly in cancer treatment. Cristal Therapeutics focuses on creating versatile nanomedicine solutions that can facilitate better outcomes in various therapeutic areas through innovative polymeric constructs.

VIVOLTA specializes in the contract development and manufacturing of electrospun medical products, focusing on nanofiber-based solutions that promote the body's natural healing processes. The company has developed advanced electrospinning technologies that enable the production of medical implants, effectively replicating the human extracellular matrix in a reproducible and scalable manner. VIVOLTA's offerings include various methods such as melt electrospinning, wet electrospinning, and emulsion electrospinning, along with specialized modules and tools that enhance the efficiency of electrospinning research. Through these innovations, VIVOLTA supports medical professionals in advancing their medical concepts and improving patient outcomes.